TABLE 2.
Demographic and clinical characteristics of the study population by type of treatment
| Placebo (n = 119) | Active control monotherapy (n = 1195) | Olmesartan monotherapy (n = 1410) | Active control dual combination (n = 79) | Olmesartan dual combination therapy (n = 637) | Olmesartan triple combination therapy (n = 102) | P value | All (n = 3542) | |
| Age (years) | 53.0 ± 10.7 | 58.0 ± 12.1 | 57.4 ± 12.0 | 56.2 ± 10.7 | 56.5 ± 10.2 | 56.9 ± 11.4 | 0.0001a | 57.3 ± 11.7 |
| Elderly | 18 (15.1) | 436 (36.5) | 477 (33.8) | 17 (21.5) | 146 (22.9) | 28 (27.5) | 0.0001a | 1122 (31.7) |
| Male sex | 63 (52.9) | 702 (58.7) | 855 (60.6) | 49 (62.0) | 408 (64.1) | 49 (48.0) | 0.015b | 2126 (60.0) |
| Height (cm) | 169.5 ± 10.1 | 168.2 ± 9.9 | 168.4 ± 9.4 | 171.7 ± 11.4 | 165.9 ± 9.4 | 168.6 ± 11.0 | 0.0001a | 168.0 ± 9.7 |
| Body weight (kg) | 79.4 ± 13.3 | 80.3 ± 17.3 | 78.7 ± 15.4 | 95.9 ± 23.3 | 77.0 ± 19.5 | 90.3 ± 19.9 | 0.0001a | 79.7 ± 17.4 |
| BMI (kg/m2) | 27.6 ± 3.6 | 28.2 ± 4.7 | 27.6 ± 4.1 | 32.4 ± 6.5 | 27.8 ± 5.7 | 31.7 ± 5.9 | 0.0001a | 28.1 ± 4.8 |
| Obese | 35 (29.4) | 333 (27.9) | 330 (23.4) | 51 (64.6) | 169 (26.5) | 57 (55.9) | 0.0001a | 975 (27.5) |
| Region | ||||||||
| Europe | 78 (65.6) | 585 (49.0) | 795 (56.4) | – | – | – | 0.0001a | 1458 (41.2) |
| USA | 41 (34.5) | 379 (31.7) | 386 (27.4) | 79 (100.0) | 198 (31.1) | 102 (100.0) | 1185 (33.5) | |
| Japan | – | 231 (19.3) | 229 (16.2) | – | 439 (68.9) | – | 899 (25.4) | |
| Race | ||||||||
| White | 10.5 (88.2) | 852 (71.3) | 1061 (75.2) | 62 (78.5) | 145 (22.8) | 75 (73.5) | 0.0001a | 2300 (64.9) |
| Asian | 1 (0.8) | 242 (20.3) | 239 (17.0) | – | 444 (69.7) | 3 (2.9) | 929 (26.2) | |
| Hispanic | 8 (6.7) | 53 (4.4) | 70 (5.0) | – | – | – | 131 (3.7) | |
| African-American | 5 (4.2) | 47 (3.9) | 38 (2.7) | 15 (19.0) | 46 (7.2) | 23 (22.5) | 174 (4.9) | |
| Other | – | 1 (0.1) | 2 (0.1) | 2 (2.5) | 2 (0.3) | 1 (1.0) | 8 (0.2) | |
| Coronary heart disease | 4 (3.4) | 37 (3.1) | 43 (3.0) | 1 (1.3) | 9 (1.4) | 6 (5.9) | 0.090 | 100 (2.8) |
| Heart failure | 1 (0.8) | – | 5 (0.4) | 1 (1.3) | – | – | 0.027b | 7 (0.2) |
| Diabetes mellitus | 9 (7.6) | 139 (11.6) | 149 (10.6) | 9 (11.4) | 113 (17.7) | 23 (22.5) | 0.0001a | 442 (12.5) |
| Cardiovascular disease | 13 (10.9) | 173 (14.5) | 187 (13.3) | 10 (12.7) | 119 (18.7) | 27 (26.5) | 0.0001a | 529 (14.9) |
| Sitting office SBP (mmHg) | 158.2 ± 12.9 | 158.3 ± 11.7 | 157.3 ± 12.6 | 163.8 ± 16.2 | 157.5 ± 13.6 | 166.3 ± 13.5 | 0.0001a | 158.1 ± 12.7 |
| Sitting office DBP (mmHg) | 102.6 ± 5.1 | 99.7 ± 7.8 | 100.1 ± 7.4 | 99.1 ± 9.0 | 98.0 ± 7.4 | 98.8 ± 7.3 | 0.0001a | 99.6 ± 7.5 |
| Sitting office HR (bpm) | 75.9 ± 8.5 | 73.3 ± 9.0 | 73.9 ± 9.5 | 73.6 ± 11.2 | 71.8 ± 9.2 | 75.9 ± 11.4 | 0.0001a | 73.4 ± 9.4 |
| 24-h SBP (mmHg) | 148.7 ± 10.5 | 148.9 ± 13.9 | 147.6 ± 13.3 | 148.0 ± 13.0 | 154.2 ± 13.0 | 146.3 ± 13.4 | 0.0001a | 149.2 ± 13.6 |
| 24-h DBP (mmHg) | 93.8 ± 6.0 | 91.0 ± 9.7 | 91.1 ± 9.2 | 88.9 ± 10.3 | 94.0 ± 9.7 | 86.2 ± 9.5 | 0.0001a | 91.5 ± 9.5 |
| 24-h HR (mmHg) | 79.9 ± 9.7 | 74.9 ± 10.1 | 75.4 ± 10.3 | 77.0 ± 10.9 | 71.9 ± 9.2 | 77.0 ± 10.5 | 0.0001a | 74.8 ± 10.2 |
Data are shown as means (± SD) or as absolute (n) and relative (%) frequencies. P values for differences across the study groups are also reported. HR, heart rate.
aP < 0.0001.
bP < 0.05.